Published in Cancer Weekly, March 15th, 2005
These leading medical research universities have chosen Reveal G2 over other FDA- approved rapid HIV tests after routine evaluations. A recently released report by Stanford and Duke Universities shows the cost benefits of increased national HIV testing in the United States.
MedMira had announced previously that Reveal G2 was the number one choice for U.S....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.